Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

BACKGROUND: Advanced biliary cancer is often treated with fluoropyrimidine-based chemotherapy. In this study, we evaluated the efficacy and tolerability of a combination of S-1, an oral fluoropyrimidine prodrug, and oxaliplatin in patients with metastatic biliary cancer. METHODS: Patients with histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, K-p, Jang, G, Hong, Y S, Lim, H-S, Bae, K-s, Kim, H-S, Lee, S S, Shin, J-G, Lee, J-L, Ryu, M-H, Chang, H-M, Kang, Y-K, Kim, T W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049596/
https://www.ncbi.nlm.nih.gov/pubmed/21326246
http://dx.doi.org/10.1038/bjc.2011.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049596/
https://www.ncbi.nlm.nih.gov/pubmed/21326246
http://dx.doi.org/10.1038/bjc.2011.17

Ejemplares similares